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Abstract
Cholesteryl ester transfer protein (CETP) inhibition reduces vascular event risk, but confu-
sion surrounds its effects on low-density lipoprotein (LDL) cholesterol. Here, we clarify asso-
ciations of genetic inhibition of CETP on detailed lipoprotein measures and compare those
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to genetic inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR). We
used an allele associated with lower CETP expression (rs247617) to mimic CETP inhibition
and an allele associated with lower HMGCR expression (rs12916) to mimic the well-known
effects of statins for comparison. The study consists of 65,427 participants of European
ancestries with detailed lipoprotein subclass profiling from nuclear magnetic resonance
spectroscopy. Genetic associations were scaled to 10% reduction in relative risk of coronary
heart disease (CHD). We also examined observational associations of the lipoprotein sub-
class measures with risk of incident CHD in 3 population-based cohorts totalling 616 incident
cases and 13,564 controls during 8-year follow-up. Genetic inhibition of CETP and HMGCR
resulted in near-identical associations with LDL cholesterol concentration estimated by the
Friedewald equation. Inhibition of HMGCR had relatively consistent associations on lower
cholesterol concentrations across all apolipoprotein B-containing lipoproteins. In contrast,
the associations of the inhibition of CETP were stronger on lower remnant and very-low-
density lipoprotein (VLDL) cholesterol, but there were no associations on cholesterol con-
centrations in LDL defined by particle size (diameter 18–26 nm) (−0.02 SD LDL defined by
particle size; 95% CI: −0.10 to 0.05 for CETP versus −0.24 SD, 95% CI −0.30 to −0.18 for
HMGCR). Inhibition of CETP was strongly associated with lower proportion of triglycerides
in all high-density lipoprotein (HDL) particles. In observational analyses, a higher triglyceride
composition within HDL subclasses was associated with higher risk of CHD, independently
of total cholesterol and triglycerides (strongest hazard ratio per 1 SD higher triglyceride com-
position in very large HDL 1.35; 95% CI: 1.18–1.54). In conclusion, CETP inhibition does not
appear to affect size-specific LDL cholesterol but is likely to lower CHD risk by lowering con-
centrations of other atherogenic, apolipoprotein B-containing lipoproteins (such as remnant
and VLDLs). Inhibition of CETP also lowers triglyceride composition in HDL particles, a phe-
nomenon reflecting combined effects of circulating HDL, triglycerides, and apolipoprotein B-
containing particles and is associated with a lower CHD risk in observational analyses. Our
results reveal that conventional composite lipid assays may mask heterogeneous effects of
emerging lipid-altering therapies.
Introduction
Definitive evidence on the causal role of low-density lipoproteins (LDLs) in cardiovascular dis-
ease comes from trials of LDL cholesterol lowering compounds [1], which have shown benefi-
cial effects on risk of coronary heart disease (CHD) and stroke. Consistent effects have been
seen for drugs acting on related pathways, such as 3-hydroxy-3-methylglutaryl-coenzyme A
reductase (HMGCR) inhibitors, i.e., statins, and proprotein convertase subtilisin-kexin type 9
(PCSK9) inhibitors [2], both of which up-regulate hepatic LDL receptor expression, and for
drugs acting on other pathways, such as ezetimibe [3], which inhibits intestinal absorption of
cholesterol [4].
However, trials of drugs primarily designed to alter concentrations of lipids other than LDL
cholesterol have had mixed results [5,6]. One such example is the class of drugs designed to
inhibit cholesteryl ester transfer protein (CETP), a lipid transport protein responsible for the
exchange of triglycerides and cholesteryl esters between apolipoprotein B-containing particles
and high-density lipoprotein (HDL) particles. CETP inhibitors were developed initially on the
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basis of their HDL cholesterol raising effects. Although accumulating genetic evidence suggests
that HDL cholesterol concentration is unlikely to be causally related to CHD [7–9], there were
2 strong reasons to believe that CETP inhibition may still reduce vascular risk: (i) genetic stud-
ies of CETP variants have shown associations with CHD [10,11] and (ii) some CETP inhibitors
not only increase HDL cholesterol but also appear to lower LDL cholesterol as measured by
conventional assays [12,13].
The findings from the phase III REVEAL study, the largest CETP trial to date, showed that
treatment with the CETP inhibitor anacetrapib led to a reduction in risk of coronary events
that was proportional to the reduction in non-HDL cholesterol [14]. Interestingly, anacetrapib
appeared to have discrepant effects based on the assay used to quantify LDL cholesterol (using
beta-quant, direct or Friedewald estimation) [13]. This discrepant effect was also identified in
a genetic study that approximated a factorial clinical trial of CETP inhibition and statin ther-
apy [15]. Thus, although both CETP inhibitors and statins lower Friedewald-estimated LDL
cholesterol, which also includes cholesterol carried by other lipoprotein particles, it is possible
that the drugs have differential effects on the concentration and composition of lipids in differ-
ent apolipoprotein B–containing lipoproteins.
In this study, we used the established approach of exploiting genetic variants near the pro-
tein-coding genes of drug targets to investigate detailed lipid and lipoprotein subclass signa-
tures of CETP inhibition in large population-based studies. We compared the association of
an allele associated with lower CETP expression (to mimic CETP inhibition) with HMGCR
expression associated variant (to proxy statin treatment) to gauge into how these 2 therapies
alter the lipoprotein milieu. The genetic effects of HMGCR inhibition were analysed to provide
a valuable control because these effects are already well understood [16]. We also examined
the role of lipoprotein composition in CHD for the first time. We present findings that the tri-
glyceride composition, in contrast to circulating concentrations, of HDL particles is associated
with CHD.
Results
Data from 62,400 individuals with extensive lipoprotein subclass profiling and genotypes were
available. We combined data from 5 adult cohorts (mean age range from 31–52 years) and one
cohort of adolescents (mean age 16 years) for the genetic analyses in which 51% of participants
of all 6 studies were female. Study-specific and pooled estimates from meta-analyses of genetic
and observational analyses for all 191 traits are presented in Supporting S1–S15 Figs.
Scaled to 10% reduction in relative risk of CHD, CETP rs247617 and HMGCR rs12916 had
near-identical associations with Friedewald-estimated LDL cholesterol (Fig 1) and similar associ-
ations for apolipoprotein B. In contrast, when LDL cholesterol was defined on the basis of choles-
terol transported in LDL based on particle size (diameter 18–26 nm) and measured via nuclear
magnetic resonance (NMR) spectroscopy, CETP expression lowering allele had no association
with this size-specific LDL cholesterol (0.02 SDs; 95% CI: −0.10 to 0.05). Although HMGCR
expression lowering allele had a relatively consistent association with individual apolipoprotein
B–containing lipoproteins (effect estimates ranging from −0.25 for intermediate-density lipopro-
tein [IDL] cholesterol to −0.18 for very-low-density lipoprotein [VLDL] cholesterol), CETP
expression lowering allele had the most pronounced associations with VLDL cholesterol, a
weaker association with IDL cholesterol, but no association with LDL cholesterol defined by par-
ticle size or cholesterol transported by any of the large, medium, or small LDL subclasses (Fig 1).
When examining triglycerides in apolipoprotein B–containing particles, CETP expression
lowering allele associated with lower circulating triglyceride concentrations in VLDL and IDL
subclasses, whereas HMGCR expression lowering allele had weaker effects on these measures,
Lipoprotein Signatures of CETP and HMGCR
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except in LDL subclasses (Fig 2). CETP expression lowering allele had a very strong association
with higher HDL cholesterol (0.84; 95% CI: 0.76–0.92) but HMGCR did not (0.04; 95% CI:
−0.02 to 0.10; Fig 3). Similarly, CETP expression lowering allele was associated with lower total
quantity of triglycerides in HDL particles (−0.23; 95% CI: −0.31 to −0.15) but HMGCR expres-
sion lowering allele was not (−0.03; 95% CI: −0.09 to 0.02).
The lipoprotein particle structure is biophysically constrained, generating strong correla-
tions between lipid measures within individual lipoprotein subclasses [19–22]. Notable differ-
ences in lipid concentrations in subclass particles would therefore suggest changes in the
compositional proportions of these lipids. For genetic inhibition of CETP, the effects on circu-
lating triglyceride concentrations in all HDL subclasses were weaker (XL-HDL and L-HDL) or
even in the opposite direction (M-HDL and S-HDL) than the effects on cholesterol concentra-
tion in these subclasses (Fig 3). Examining the genetic associations with the particle lipid com-
positions, the relative amount of triglycerides (in relation to all lipid molecules in the particles)
was remarkably diminished in all HDL subclass particles by genetic inhibition of CETP (Fig
4). Genetic inhibition of HMGCR did not associate with triglyceride concentration or compo-
sition of any HDL subclass. These associations are in line with the known physiological roles
of CETP and HMGCR and their inhibition [23,24]. In addition, as expected, CETP expression
lowering allele associated with higher compositions of triglycerides in most VLDL subclass
Fig 1. Associations of genetic variants in CETP rs247617 (red) andHMGCR rs12916 (blue) with circulating
apolipoprotein B and cholesterol concentrations in size-specific apolipoprotein B particles. Estimates represent the
standardized difference in lipoprotein trait, with per allele associations scaled to a 10% lower relative risk of CHD.
Analyses were adjusted for age, sex, genotyping batch, and 10 genetic principal components. The circles refer to the
effect estimates and the horizontal bars to the 95% CIs. Closed circles represent statistical significance of associations at
P< 0.002 and open circles associations that are nonsignificant at this threshold. The lipoprotein subclasses are defined
by particle size [17–19]: potential chylomicrons and the largest VLDL particles (XXL-VLDL; average particle diameter
�75 nm); 5 different VLDL subclasses, i.e., very large (average particle diameter 64.0 nm), large (53.6 nm), medium
(44.5 nm), small (36.8 nm), and very small VLDL (31.3 nm); IDL (28.6 nm); and 3 LDL subclasses, i.e., large (25.5 nm),
medium (23.0 nm), and small LDL (18.7 nm). Underlying data can be found in S1 Data. ApoB, apolipoprotein B; C,
cholesterol; CHD, coronary heart disease; IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; VLDL,
very-low-density lipoprotein.
https://doi.org/10.1371/journal.pbio.3000572.g001
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particles and HMGCR expression lowering allele showed directionally similar albeit weaker
associations.
To understand the clinical relevance of these HDL-related compositional changes arising
from CETP inhibition, beyond lowering the cholesterol concentrations of apolipoprotein B–
containing lipoprotein particles, we studied the observational associations of lipoprotein sub-
class lipid concentrations and compositions with CHD in 3 prospective population cohorts
totalling 616 incident cases and 13,564 controls during an 8-year follow-up. The triglyceride
concentration of HDL was associated with incident CHD when adjusted for nonlipid cardio-
vascular risk factors (Fig 5). However, when serum cholesterol and serum triglycerides were
added to the model, as expected, the associations attenuated. In contrast, the triglyceride com-
positions of all the HDL subclass particles were positively associated with CHD, independent
of circulating concentrations of cholesterol and triglycerides, with hazard ratios around 1.3 for
all HDL subclasses (Fig 5). Adjusting for LDL-C had only very minor effects on the associa-
tions of both circulating HDL-related triglyceride concentrations and the triglyceride compo-
sitions of HDL particles. In addition to the compositional enrichment of triglycerides in HDL
particles, the compositional enrichment of cholesteryl esters in the largest VLDL particles
(XXL-VLDL and XL-VLDL) was also observationally associated with greater risk of CHD (S11
Fig). The genetic inhibition of CETP lowered the cholesteryl ester composition of these VLDL
particles, i.e., was acting toward decreased risk of CHD (S2 Fig).
Fig 2. Associations of genetic variants in CETP rs247617 (red) andHMGCR rs12916 (blue) with circulating
triglyceride concentrations in size-specific apolipoprotein B particles. Estimates represent the standardized
difference in lipoprotein trait, with per allele associations scaled to a 10% lower relative risk of CHD. Analyses were
adjusted for age, sex, genotyping batch, and 10 genetic principal components. The circles refer to the effect estimates
and the horizontal bars to the 95% CIs. Closed circles represent statistical significance of associations at P< 0.002 and
open circles associations that are nonsignificant at this threshold. The lipoprotein subclasses are defined by particle size
[17–19]: potential chylomicrons and the largest VLDL particles (XXL-VLDL; average particle diameter�75 nm); 5
different VLDL subclasses, i.e., very large (average particle diameter 64.0 nm), large (53.6 nm), medium (44.5 nm),
small (36.8 nm), and very small VLDL (31.3 nm); IDL (28.6 nm); and 3 LDL subclasses, i.e., large (25.5 nm), medium
(23.0 nm), and small LDL (18.7 nm). Underlying data can be found in S1 Data. CHD, coronary heart disease; IDL,
intermediate-density lipoprotein; LDL, low-density lipoprotein; TG, triglyceride; VLDL, very-low-density lipoprotein.
https://doi.org/10.1371/journal.pbio.3000572.g002
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To further investigate the novel relation of the triglyceride composition of HDL particles
(and thereby potentially the inhibition of CETP) with incident CHD, we performed systematic
analyses focusing on 3 fundamental measures that characterize the overall lipoprotein profile
fairly well, namely, total serum triglyceride, HDL-C, and apolipoprotein B concentration, and
gradually adjusted the association between HDL particle triglyceride composition and incident
CHD. The results are presented in Fig 6. Adjusting the associations between HDL particle tri-
glyceride compositions and incident CHD with total triglycerides, HDL-C and apolipoprotein
B had all very similar minor effects. However, a combined adjustment for apolipoprotein B
and HDL-C almost abolished the associations similarly to apolipoprotein B and triglycerides.
Discussion
We used genetic variants in CETP and HMGCR to gain insight into the expected effects of
therapeutic inhibition of CETP and HMG-CoA reductase on circulating lipoproteins and lip-
ids. Our data show that although CETP and HMGCR have near-identical effects on Friede-
wald-estimated LDL cholesterol, this result masks a very different association of CETP and
HMGCR with size-specific LDL cholesterol. Genetic inhibition of HMGCR showed similar
effects with cholesterol across the apolipoprotein B–containing lipoproteins but genetic inhibi-
tion of CETP showed stronger associations with larger apolipoprotein B particles, namely,
VLDL and remnant cholesterol [25], but no association with cholesterol carried specifically in
LDL particles defined by size.
Fig 3. Associations of genetic variants in CETP rs247617 (red) andHMGCR rs12916 (blue) with circulating
apolipoprotein A-I as well as cholesterol and triglyceride concentrations in size-specific HDL particles. Estimates
represent the standardized difference in lipoprotein trait, with per allele associations scaled to a 10% lower relative risk
of CHD. Analyses were adjusted for age, sex, genotyping batch, and 10 genetic principal components. The circles refer
to the effect estimates and the horizontal bars to the 95% CIs. Closed circles represent statistical significance of
associations at P< 0.002 and open circles associations that are nonsignificant at this threshold. The lipoprotein
subclasses are defined by particle size [17–19]: the 4 size-specific HDL subclasses are very large (average particle
diameter 14.3 nm), large (12.1 nm), medium (10.9 nm), and small HDL (8.7 nm). Underlying data can be found in S1
Data. Apo A-I, apolipoprotein A-I; C, cholesterol; CHD, coronary heart disease; HDL, high-density lipoprotein; TG,
triglycerides.
https://doi.org/10.1371/journal.pbio.3000572.g003
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Friedewald-estimated LDL cholesterol (as well as ‘direct’ assays) are nonspecific measures
of cholesterol [26–28]. For example, in addition to the cholesterol in size-specific LDL parti-
cles, Friedewald LDL cholesterol also includes, to varying degrees, cholesterol in IDL, VLDL,
and lipoprotein(a) [29]. This nonspecificity of commonly used “LDL” cholesterol assays is
under-recognized and underlies the prevailing opinion that inhibitors of HMGCR and CETP
both alter LDL cholesterol. However, our data show this not to be the case: using NMR spec-
troscopy-based lipoprotein particle quantification, which defines individual lipoprotein sub-
classes based on particle size [18,19,21], our findings demonstrate that CETP has negligible
effect on cholesterol in size-specific LDL particles. As the inhibition of CETP affects the IDL
subclass similarly to all the LDL subclasses, the “LDL cholesterol” via beta-quantification
would also be only minimally affected. In this way, the use of a composite lipid measure can
obscure differential associations of a therapy or gene [20] with individual constituents of the
composite and can have clinical ramifications. For example, if a trial is powered to a given
reduction in Friedewald LDL cholesterol, under the naïve assumption that the drug uniformly
alters all the subcomponents, then the trial may not have the expected result if the drug has dif-
ferential effects on these subcomponents. This is exemplified in the recent phase III ACCEL-
ERATE trial of evacetrapib, which was terminated for futility, and was powered to a difference
Fig 4. Associations of genetic variants in CETP rs247617 (red) andHMGCR rs12916 (blue) with the triglyceride
composition of size-specific lipoprotein particles. Estimates represent the standardized difference in lipoprotein
trait, with per allele associations scaled to a 10% lower relative risk of CHD. Analyses were adjusted for age, sex,
genotyping batch, and 10 genetic principal components. The circles refer to the effect estimates and the horizontal bars
to the 95% CIs. Closed circles represent statistical significance of associations at P< 0.002 and open circles associations
that are nonsignificant at this threshold. The lipoprotein subclasses are defined by particle size [17–19]: potential
chylomicrons and the largest VLDL particles (XXL-VLDL; average particle diameter�75 nm); 5 different VLDL
subclasses, i.e., very large (average particle diameter 64.0 nm), large (53.6 nm), medium (44.5 nm), small (36.8 nm),
and very small (31.3 nm); IDL (28.6 nm); and 3 LDL subclasses, i.e., large (25.5 nm), medium (23.0 nm), and small
(18.7 nm). The 4 size-specific HDL subclasses are very large (average particle diameter 14.3 nm), large (12.1 nm),
medium (10.9 nm), and small (8.7 nm). Underlying data can be found in S1 Data. Apo B, apolipoprotein B; CHD,
coronary heart disease; HDL, high-density lipoprotein; IDL, intermediate-density lipoprotein; LDL, low-density
lipoprotein; TG, triglycerides; VLDL, very-low-density lipoprotein.
https://doi.org/10.1371/journal.pbio.3000572.g004
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Fig 5. Observational associations of circulating triglyceride concentrations and triglyceride composition in lipoprotein subclass particles and risk
of incident CHD. (Left panel) Black: Hazard ratios for incident CHD per SD higher triglyceride concentration within each size-specific lipoprotein
subclass adjusted for traditional risk factors. Pink: adjusted for traditional risk factors, serum cholesterol, and serum triglycerides. (Right panel) Black:
Hazard ratios for incident CHD per SD higher percentage of triglycerides (of all lipid molecules) within each size-specific lipoprotein subclass adjusted
for traditional risk factors. Pink: adjusted for traditional risk factors, serum cholesterol, and serum triglycerides. Basic risk factors include age, sex, mean
arterial pressure, smoking, diabetes mellitus, lipid medication, geographical region in FINRISK, and ethnicity in SABRE. The horizontal bars to the 95%
CIs. Closed circles represent statistical significance of associations at P< 0.002 and open circles associations that are nonsignificant at this threshold. The
horizontal bars refer to the 95% CIs. Underlying data can be found in S1 Data. Apo B, apolipoprotein B; CHD, coronary heart disease; HDL, high-
density lipoprotein; IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; VLDL, very-low-density lipoprotein; TG, triglycerides.
https://doi.org/10.1371/journal.pbio.3000572.g005
Fig 6. Observational associations of circulating triglyceride concentrations and triglyceride composition in lipoprotein subclass particles and risk of incident
CHD with multiple adjustments. Hazard ratios for incident CHD per SD higher circulating triglyceride concentrations (upper part) and triglyceride composition
(lower part) in lipoprotein subclass particles within each size-specific lipoprotein subclass adjusted for traditional risk factors and gradually for 3 fundamental measures
that characterize the overall lipoprotein profile pretty well, namely, total serum triglyceride (total TG), HDL cholesterol (HDL-C), and apolipoprotein B (apoB)
concentration. Closed circles represent statistical significance of associations at P< 0.002 and open circles associations that are nonsignificant at this threshold. The
horizontal bars refer to the 95% CIs. Underlying data can be found in S1 Data. Apo B, apolipoprotein B; C, cholesterol; CHD, coronary heart disease; HDL, high-density
lipoprotein; IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; TG, triglycerides; VLDL, very-low-density lipoprotein.
https://doi.org/10.1371/journal.pbio.3000572.g006
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in LDL cholesterol based on a composite assay [12]. The differential effects of CETP inhibition
on composite markers such as Friedewald and directly-quantified LDL cholesterol compared
to apolipoprotein B concentrations identified in the subsequent phase III REVEAL trial of ana-
cetrapib [13] suggest that had ACCELERATE used an alternative measure of proatherogenic
lipoproteins (e.g., apolipoprotein B or non-HDL-C [14]) to gauge the expected vascular effect,
the trial may have been more appropriately powered.
This highlights the need to understand, in detail, the consequences of lipid-modifying ther-
apies on lipoproteins and lipids in order to be able to gauge whether a composite measure
(such as Friedewald LDL cholesterol) can be reliably used as an indicator of the likely benefi-
cial effect of a therapy. This is unlikely to be limited to assays for LDL cholesterol. For example,
assays that quantify triglycerides measure the summation of triglycerides across multiple lipo-
protein particle categories. Drugs currently under development that target triglycerides (such
as apolipoprotein C-III inhibitors [30]) have differential effects on triglycerides in lipoprotein
subclass particles as demonstrated in a recent genetic study [31]. If triglycerides within differ-
ent lipoprotein subclasses have heterogeneous effects on vascular disease, a clinical trial pow-
ered to the overall concentration of circulating triglycerides may give an inaccurate portrayal
of the cardiovascular consequences arising from apolipoprotein C-III inhibition.
Another key finding is that the lipid compositions of lipoprotein particles can associate
with disease risk independently of total lipid concentrations. Although genetic inhibition of
CETP increased circulating concentrations of cholesterol in all HDL subclasses, the triglycer-
ide composition, i.e., the percentage of triglyceride molecules of all the lipid molecules in the
particle, was markedly lower in all HDL particles. Intriguingly, our observational analyses, the
first to explore lipoprotein particle lipid composition with CHD outcomes, revealed that tri-
glyceride enrichment of HDL particles associates with higher risk for future CHD, indepen-
dently of total circulating cholesterol and triglycerides. The largest hazard ratio for the
triglyceride enrichment in medium HDL subclass particles was of a similar magnitude
(approximately 1.3) as that for LDL cholesterol and apolipoprotein B [32]. However, this phe-
nomenon appears to be due to combined effects of circulating HDL and apolipoprotein B-con-
taining particles, maybe in connection to CETP function and the circulating amount of total
triglycerides, not an intrinsic indication of the role of HDL particle lipid composition in CHD.
Key strengths of our analyses include the availability of detailed measurements of blood
lipoprotein subclass concentrations and compositions from general population studies with
incident CHD events, together with the availability of genome-wide genotyping. We used sin-
gle CETP and HMGCR variants as genetic proxies for therapeutic inhibition (i.e., instruments
in the Mendelian randomization analyses), assuming that they are not pleiotropic. This
assumption is justifiable on the basis that the SNPs were selected in cis-regions and alter gene
expression and together with the fact that (1) the CETP genetic variant recapitulated the effects
of CETP enzyme activity in relation to the role the enzyme has in shuttling esterified choles-
terol from HDL to apolipoprotein B-containing particles in exchange for triglycerides [23] and
that (2) prospective population-based data of patients taking statins with blood sampling
before and after the commencement of therapy showed that genetic variants in HMGCR
robustly recapitulated the effects of statin therapy on lipoprotein subclasses and lipids [16].
In conclusion, we have shown that, in contrast to genetic inhibition of HMG-CoA (proxy-
ing statin therapy), genetic inhibition of CETP does not alter circulating size-specific LDL cho-
lesterol concentrations. This is masked by using conventional, nonspecific assays for LDL
cholesterol and may be problematic for ongoing and future clinical trials of lipid lowering ther-
apies, especially when a nonspecific marker of lipids is used to derive an expected effect of a
drug with risk of disease. The basis for the reduction in CHD risk seen with CETP inhibition
appears to be due to the lowering of atherogenic non-LDL lipoprotein particles. Our findings
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draw attention to the need for metabolic precision in measurements of lipoprotein lipids and
subclasses and in assessing the role of lipoprotein metabolism in cardiovascular disease in rela-
tion to ongoing treatment trials of novel lipid-altering therapies.
Methods
Ethics statement
The Ethics Committee of the Faculty of Medicine, University of Oulu has approved the North-
ern Finland Birth Cohort 1986 (NFBC86) (17.6.1999) and the Northern Finland Birth Cohort
1966 (NFBC66) studies (17.6.1996). In addition, the Ethics Committee of the Northern Ostro-
bothnia Hospital District has approved the NFBC66 (94/2011) and NFBC86 (108/2017). This
study has been approved by the NFBC Scientific Committee (material request P0268/2018).
The Cardiovascular Risk in Young Finns Study (YFS) was approved by the following Ethics
Committees covering all the 5 participating medical university study sites in Finland: the Eth-
ics Committee of the Hospital District of Southwest Finland (12/2007 §533, 19.12.2006; 8/2007
§330, 28.8.2007; 1/2008 §28, 15.1.2008), the Ethics Committee of the Pirkanmaa Hospital Dis-
trict (ETL-R07100), and the Ethics Committee of the Northern Ostrobothnia Hospital District
(84/2001). The FINRISK 1997 was approved by the Ethics committee of the National Public
Health Institute, Helsinki, Finland (23.01.1997), and the DILGOM 2007 study was approved
by the Ethics Committee of the Helsinki and Uusimaa Hospital District (229/E0/2006). The
SABRE study protocols were approved by the University College London (5.1.1988/PMcK/sp)
and by the St. Mary’s Hospital Research Ethics Committee (07/H0712/109). The INTERVAL
study was approved by the Cambridge (East) Research Ethics Committee (11/EE/0538/74247)
and was also approved by the University of Cambridge’s Research Operations Office and the
Research Governance Office. All studies were approved by local institutional research review
committees, and all clinical investigations were conducted according to the principles
expressed in the Declaration of Helsinki. All participants gave written informed consents.
Prospective and cross-sectional studies and lipoprotein quantification
We used genetic and lipoprotein data from 5 population-based Finnish cohorts and 1 cross-
sectional study in the UK (cohort characteristics are presented in S1 Table and study descrip-
tions are given in S1 Text). Details of study-specific genotyping are provided in S2 Table.
Briefly, the cohorts used were the NFBC66 (n = 4,702 individuals aged 31 y at blood draw)
[33,34], the NFBC86 (n = 3,726 individuals aged 16 y at blood draw), the YFS (n = 1,948 indi-
viduals aged 24–39 y in 2007) [35], 2 population-based Finnish cohorts FINRISK 1997
(n = 6,942 individuals aged 24–74 y) and DILGOM subsample of FINRISK 2007 (n = 4,124
individuals aged 24–74 y) [36,37], and a study of healthy blood donors from the UK (INTER-
VAL: n = 40,958 individuals aged 18–80 y) [38]. For prospective analyses, we used the above-
mentioned FINRISK 1997 and DILGOM cohorts and additionally a tri-ethnic UK
community-based cohort SABRE (n = 4,976 individuals aged 40–69 y) [39,40]. The focus in
this study was to evaluate the impact of variants in CETP (and HMGCR) on lipoprotein metab-
olism, i.e., on the entire cascade of apolipoprotein B–containing lipoproteins and HDL sub-
classes. Therefore, we decided a priori to examine all the 191 lipoprotein and lipid traits
available from the NMR-based methodology [17]. Abbreviations and full descriptions of the
lipoprotein measures are given in S3 Table. Details of this platform have been published previ-
ously [17,41], and it has been widely applied in genetic and epidemiological studies [16,18,42–
44]. Focusing on these 191 traits, we estimated that 28 principal components explain 99% of
their variation in the Finnish cohorts, and therefore we used a P value threshold of 0.05/
28 = 0.002 to denote evidence in favor of an association.
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Where possible, we excluded individuals receiving lipid lowering medication, pregnant
women, and those who had a high proportion (>30%) of values missing across the lipid traits;
details are given in S1 Text. All measures (S3 Table) were first adjusted for sex, age (if applica-
ble), genotyping batch (if applicable), and 10 first principal components from genomic data,
and the resulting residuals were transformed to normal distribution by inverse rank-based
normal transformation.
Selection of genetic variants and genetic analyses
We selected variants as genetic proxies of CETP and HMGCR inhibition on the basis of robust
associations with circulating lipids in GWAS consortia [42,45] and target gene expression. The
HMGCR variant (rs12916) LDL cholesterol lowering T allele (−0.24 SD LDL cholesterol per T
allele; P = 1.3 × 10−14) has been shown to lower HMGCR expression [46,47], and the CETP var-
iant (rs247617) HDL cholesterol increasing A allele (0.84 SD HDL cholesterol per A allele;
P = 5.4 × 10−94) associates with lower CETP gene expression. Rs247617 is the strongest eQTL
for CETP across all tissues in Genotype To Expression (https://gtexportal.org) project data
[48]. Thus, we use these variants as biologically plausible instruments in the Mendelian ran-
domization framework to infer the drug effects through genetic inhibition of these genes
[6,33]. We used an additive model for each cohort separately (see S1 Table for details of analy-
sis software). In order to make the lipoprotein and lipid estimates comparable, the estimates
for CETP rs247617 and HMGCR rs12916 were scaled to the same CHD association as reported
by the CARDIoGRAMplusC4D GWAS Consortium [49]. The per allele log odds (logOR) for
CHD was 0.0358 (standard error = 0.01, P = 1.6 × 10−4 and T allele frequency 0.57) for
HMGCR rs12916 and 0.0309 (standard error = 0.01, P = 2.5 × 10−3 and C allele frequency
0.69) for CETP rs247617; subsequently, the summary statistics of each individual cohort and
each metabolite were scaled to −0.105 logOR of CHD (equivalent to an odds ratio [OR] of
CHD of 0.90) to align the estimates to a 10% lower relative risk of CHD. We use the term rela-
tive risk as a moniker of ratio effect estimates. The cohort-specific association results of lipo-
protein and lipid measures with both variants were then combined using an inverse-variance
weighted fixed effect meta-analysis.
Association of lipoprotein measures with risk of incident CHD
Cohorts contributing to the associations of lipoprotein lipid concentration and composition
measures and the hazard of incident CHD were FINRISK 1997, DILGOM, and SABRE. Partic-
ipants with prevalent CHD were excluded from the analysis. Following exclusion, data were
available from FINRISK 1997 for 6,484 individuals (287 cases/6,197 controls) and 3,318 indi-
viduals from DILGOM (270 cases/3,048 controls) and for SABRE 4,378 individuals with non-
missing data (59 cases/4,319 controls). The follow-up time of FINRISK 1997 and SABRE were
censored to 8 years to match the follow-up time in DILGOM.
Prior to statistical analyses, metabolic measures were log-transformed and scaled to SD in
each cohort. The relationships of lipid measures with the risk of CHD were analysed using
Cox proportional hazards regression models with age, sex, mean arterial pressure, smoking,
diabetes mellitus, lipid medication, and geographical region (Finnish cohorts), ethnicity
(SABRE), total cholesterol, and total triglyceride concentrations as covariates. The cohort-spe-
cific association results of 191 lipid measures were then combined using inverse-variance
weighted fixed-effects meta-analysis. Analyses were conducted in R studio (version 1.0.153, R
version 3.3.3). As above, we used a P value threshold of�0.002 to denote evidence in favor of
an association.
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Supporting information
S1 Text. Study descriptions. Overall description of the individual cohorts.
(PDF)
S1 Table. Characteristics of the study populations. Clinical characteristics for the 7 cohorts
included in the study.
(PDF)
S2 Table. Genotyping detail of the cohorts. Details of the genotyping for the 6 cohorts
including genetic data in this study.
(PDF)
S3 Table. Key for the lipid and lipoprotein abbreviations. Abbreviations and the description
of the lipid and lipoprotein subclass measures.
(PDF)
S1 Fig. Meta-analysis of genetic variants in CETP rs247617 (red) andHMGCR rs12916
(blue) for all lipoprotein concentration measures. Estimates are the standardized difference
in lipoprotein trait, with per allele associations scaled to a 10% lower relative risk of CHD. The
circles refer to the effect estimates and the horizontal bars to the 95% CIs. Closed circles repre-
sent associations at P< 0.002, and open circles show associations that are nonsignificant at
this threshold. The lipoprotein subclasses are defined by particle size: potential chylomicrons
and the largest VLDL particles (XXL-VLDL; average particle diameter�75 nm); 5 different
VLDL subclasses, i.e., very large (average particle diameter 64.0 nm), large (53.6 nm), medium
(44.5 nm), small (36.8 nm), and very small (31.3 nm); IDL (28.6 nm); and 3 LDL subclasses,
i.e., large (25.5 nm), medium (23.0 nm), and small (18.7 nm). Underlying data can be found in
S2 Data. CHD, coronary heart disease; IDL, intermediate-density lipoprotein; LDL, low-den-
sity lipoprotein; VLDL, very-low-density lipoprotein.
(TIF)
S2 Fig. Meta-analysis of genetic variants in CETP rs247617 (red) andHMGCR rs12916
(blue) for all lipoprotein composition measures. Estimates are the standardized difference in
lipoprotein trait, with per allele associations scaled to a 10% lower relative risk of CHD. The
circles refer to the effect estimates and the horizontal bars to the 95% CIs. Closed circles repre-
sent associations at P< 0.002, and open circles show associations that are nonsignificant at
this threshold. The lipoprotein subclasses are defined by particle size: potential chylomicrons
and the largest VLDL particles (XXL-VLDL; average particle diameter�75 nm); 5 different
VLDL subclasses, i.e., very large (average particle diameter 64.0 nm), large (53.6 nm), medium
(44.5 nm), small (36.8 nm), and very small (31.3 nm); IDL (28.6 nm); and 3 LDL subclasses,
i.e., large (25.5 nm), medium (23.0 nm), and small (18.7 nm). Underlying data can be found in
S2 Data. CHD, coronary heart disease; IDL, intermediate-density lipoprotein; LDL, low-den-
sity lipoprotein; VLDL, very-low-density lipoprotein.
(TIF)
S3 Fig. Meta-analysis of genetic variants in CETP rs247617 (red) andHMGCR rs12916
(blue) for all summary lipid measures. Estimates are the standardized difference in lipopro-
tein trait, with per allele associations scaled to a 10% lower relative risk of CHD. The circles
refer to the effect estimates and the horizontal bars to the 95% CIs. Closed circles represent
associations at P< 0.002, and open circles show associations that are nonsignificant at this
threshold. The lipoprotein subclasses are defined by particle size: potential chylomicrons and
the largest VLDL particles (XXL-VLDL; average particle diameter�75 nm); 5 different VLDL
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subclasses, i.e., very large (average particle diameter 64.0 nm), large (53.6 nm), medium (44.5
nm), small (36.8 nm), and very small (31.3 nm); IDL (28.6 nm); and 3 LDL subclasses, i.e.,
large (25.5 nm), medium (23.0 nm), and small LDL (18.7 nm). Underlying data can be found
in S2 Data. CHD, coronary heart disease; IDL, intermediate-density lipoprotein; LDL, low-
density lipoprotein; VLDL, very-low-density lipoprotein.
(TIF)
S4 Fig. Individual cohort associations of genetic variant in CETP rs247617 for all lipopro-
tein concentration measures. Estimates are the standardized difference in lipoprotein trait,
with per allele associations scaled to a 10% lower relative risk of CHD. The circles refer to the
effect estimates and the horizontal bars to the 95% CIs. Closed circles represent associations at
P< 0.002, and open circles show associations that are nonsignificant at this threshold. The
lipoprotein subclasses are defined by particle size: potential chylomicrons and the largest
VLDL particles (XXL-VLDL; average particle diameter�75 nm); 5 different VLDL subclasses,
i.e., very large (average particle diameter 64.0 nm), large (53.6 nm), medium (44.5 nm), small
(36.8 nm), and very small (31.3 nm); IDL (28.6 nm); and 3 LDL subclasses, i.e., large (25.5
nm), medium (23.0 nm), and small (18.7 nm). Underlying data can be found in S2 Data.
CHD, coronary heart disease; IDL, intermediate-density lipoprotein; LDL, low-density lipo-
protein; VLDL, very-low-density lipoprotein.
(TIF)
S5 Fig. Individual cohort results of CETP rs247617 for all lipoprotein composition mea-
sures. Estimates are the standardized difference in lipoprotein trait, with per allele associations
scaled to a 10% lower relative risk of CHD. The circles refer to the effect estimates and the hor-
izontal bars to the 95% CIs. Closed circles represent associations at P< 0.002, and open circles
show associations that are nonsignificant at this threshold. The lipoprotein subclasses are
defined by particle size: potential chylomicrons and the largest VLDL particles (XXL-VLDL;
average particle diameter�75 nm); 5 different VLDL subclasses, i.e., very large (average parti-
cle diameter 64.0 nm), large (53.6 nm), medium (44.5 nm), small (36.8 nm), and very small
(31.3 nm); IDL (28.6 nm); and 3 LDL subclasses, i.e., large (25.5 nm), medium (23.0 nm), and
small (18.7 nm). Underlying data can be found in S2 Data. CHD, coronary heart disease; IDL,
intermediate-density lipoprotein; LDL, low-density lipoprotein; VLDL, very-low-density lipo-
protein.
(TIF)
S6 Fig. Individual cohort associations of CETP rs247617 for all summary lipid measures.
Estimates are the standardized difference in lipoprotein trait, with per allele associations scaled
to a 10% lower relative risk of CHD. The circles refer to the effect estimates and the horizontal
bars to the 95% CIs. Closed circles represent associations at P< 0.002, and open circles show
associations that are nonsignificant at this threshold. The lipoprotein subclasses are defined by
particle size: potential chylomicrons and the largest VLDL particles (XXL-VLDL; average par-
ticle diameter�75 nm); 5 different VLDL subclasses, i.e., very large (average particle diameter
64.0 nm), large (53.6 nm), medium (44.5 nm), small (36.8 nm), and very small (31.3 nm); IDL
(28.6 nm); and 3 LDL subclasses, i.e., large (25.5 nm), medium (23.0 nm), and small (18.7 nm).
Underlying data can be found in S2 Data. CHD, coronary heart disease; IDL, intermediate-
density lipoprotein; LDL, low-density lipoprotein; VLDL, very-low-density lipoprotein.
(TIF)
S7 Fig. Individual cohort association ofHMGCR rs12916 variant for all lipoprotein con-
centration measures. Estimates are the standardized difference in lipoprotein trait, with per-
allele associations scaled to a 10% lower relative risk of CHD. The circles refer to the effect
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estimates and the horizontal bars to the 95% CIs. Closed circles represent associations at
P< 0.002, and open circles show associations that are nonsignificant at this threshold. The
lipoprotein subclasses are defined by particle size: potential chylomicrons and the largest
VLDL particles (XXL-VLDL; average particle diameter�75 nm); 5 different VLDL subclasses,
i.e., very large (average particle diameter 64.0 nm), large (53.6 nm), medium (44.5 nm), small
(36.8 nm), and very small (31.3 nm); IDL (28.6 nm); and 3 LDL subclasses, i.e., large (25.5
nm), medium (23.0 nm), and small (18.7 nm). Underlying data can be found in S2 Data.
CHD, coronary heart disease; IDL, intermediate-density lipoprotein; LDL, low-density lipo-
protein; VLDL, very-low-density lipoprotein.
(TIF)
S8 Fig. Individual cohort results ofHMGCR rs12916 association with all lipoprotein com-
position measures. Estimates are the standardized difference in lipoprotein trait, with per
allele associations scaled to a 10% lower relative risk of CHD. The circles refer to the effect esti-
mates and the horizontal bars to the 95% CIs. Closed circles represent associations at
P< 0.002, and open circles show associations that are nonsignificant at this threshold. The
lipoprotein subclasses are defined by particle size: potential chylomicrons and the largest
VLDL particles (XXL-VLDL; average particle diameter�75 nm); 5 different VLDL subclasses,
i.e., very large (average particle diameter 64.0 nm), large (53.6 nm), medium (44.5 nm), small
(36.8 nm), and very small (31.3 nm); IDL (28.6 nm); and 3 LDL subclasses, i.e., large (25.5
nm), medium (23.0 nm), and small (18.7 nm). Underlying data can be found in S2 Data.
CHD, coronary heart disease; IDL, intermediate-density lipoprotein; LDL, low-density lipo-
protein; VLDL, very-low-density lipoprotein.
(TIF)
S9 Fig. Individual cohort results ofHMGCR rs12916 associations with all summary lipid
measures. Estimates are the standardized difference in lipoprotein trait, with per allele associa-
tions scaled to a 10% lower relative risk of CHD. The circles refer to the effect estimates and
the horizontal bars to the 95% CIs. Closed circles represent associations at P< 0.002, and open
circles show associations that are nonsignificant at this threshold. The lipoprotein subclasses
are defined by particle size: potential chylomicrons and the largest VLDL particles (XXL-
VLDL; average particle diameter�75 nm); 5 different VLDL subclasses, i.e., very large (aver-
age particle diameter 64.0 nm), large (53.6 nm), medium (44.5 nm), small (36.8 nm), and very
small (31.3 nm); IDL; 28.6 nm); and 3 LDL subclasses, i.e., large (25.5 nm), medium (23.0 nm),
and small (18.7 nm). Underlying data can be found in S2 Data. CHD, coronary heart disease;
IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; VLDL, very-low-density
lipoprotein.
(TIF)
S10 Fig. Meta-analysis of incident CHD association for all lipoprotein concentration mea-
sures. Estimates represent hazard ratios for incident CHD per SD lipoprotein concentration.
Black color refers to adjusting for the traditional risk factors and pink color adjusting for the
traditional risk factors and serum cholesterol and serum triglycerides. Traditional risk factors
include age, sex, mean arterial pressure, smoking, diabetes mellitus, lipid medication, geo-
graphical region in FINRISK, and ethnicity in SABRE. Closed circles represent statistical sig-
nificance of associations at P< 0.002 and open circles associations that are nonsignificant at
this threshold. The horizontal bars refer to the 95% CIs. Underlying data can be found in S2
Data. CHD, coronary heart disease.
(TIF)
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S11 Fig. Meta-analysis of incident CHD association for all lipoprotein composition mea-
sures. Estimates represent hazard ratios for incident CHD per SD lipoprotein composition
measure. Black color refers to adjusting for the traditional risk factors and pink color adjusting
for the traditional risk factors and serum cholesterol and serum triglycerides. Traditional risk
factors include age, sex, mean arterial pressure, smoking, diabetes mellitus, lipid medication,
geographical region in FINRISK, and ethnicity in SABRE. Closed circles represent statistical
significance of associations at P< 0.002 and open circles associations that are nonsignificant
at this threshold. The horizontal bars refer to the 95% CIs. Underlying data can be found in S2
Data. CHD, coronary heart disease.
(TIF)
S12 Fig. Meta-analysis of incident CHD association for all summary lipid measures. Esti-
mates represent hazard ratios for incident CHD per SD lipoprotein measure. Black colo r
refers to adjusting for the traditional risk factors and pink color adjusting for the traditional
risk factors and serum cholesterol and serum triglycerides. Traditional risk factors include age,
sex, mean arterial pressure, smoking, diabetes mellitus, lipid medication, geographical region
in FINRISK, and ethnicity in SABRE. Closed circles represent statistical significance of associa-
tions at P< 0.002 and open circles associations that are nonsignificant at this threshold. The
horizontal bars refer to the 95% CIs. Underlying data can be found in S2 Data. CHD, coronary
heart disease.
(TIF)
S13 Fig. Individual cohort results of incident CHD association for all lipoprotein concen-
tration measures. Estimates represent hazard ratios for incident CHD per SD lipoprotein con-
centration adjusted for traditional risk factors (age, sex, mean arterial pressure, smoking,
diabetes mellitus, lipid medication, geographical region in FINRISK, and ethnicity in SABRE),
total cholesterol, and total triglycerides. Closed circles represent statistical significance of asso-
ciations at P< 0.002 and open circles associations that are nonsignificant at this threshold.
The horizontal bars refer to the 95% CIs. Underlying data can be found in S2 Data. CHD, cor-
onary heart disease.
(TIF)
S14 Fig. Individual cohort results of incident CHD association for all lipoprotein composi-
tion measures. Estimates represent hazard ratios for incident CHD per SD lipoprotein com-
position measure adjusted for traditional risk factors (age, sex, mean arterial pressure,
smoking, diabetes mellitus, lipid medication, geographical region in FINRISK, and ethnicity in
SABRE), total cholesterol, and total triglycerides. Closed circles represent statistical signifi-
cance of associations at P< 0.002 and open circles associations that are nonsignificant at this
threshold. The horizontal bars refer to the 95% CIs. Underlying data can be found in S2 Data.
CHD, coronary heart disease.
(TIF)
S15 Fig. Individual cohort results of incident CHD association for all summary lipid mea-
sures. Estimates represent hazard ratios for incident CHD per SD lipoprotein measure
adjusted for traditional risk factors (age, sex, mean arterial pressure, smoking, diabetes melli-
tus, lipid medication, geographical region in FINRISK, and ethnicity in SABRE), total choles-
terol, and total triglycerides. Closed circles represent statistical significance of associations at
P< 0.002 and open circles associations that are nonsignificant at this threshold. The horizon-
tal bars refer to the 95% CIs. Underlying data can be found in S2 Data. CHD, coronary heart
disease.
(TIF)
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S1 Data. Data underlying Figs 1–6.
(XLSX)
S2 Data. Data underlying S1–S15 Figs.
(XLSX)
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